Navigation Links
Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
Date:9/23/2009

DURHAM, N.C., Sept. 23 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This approval from the Israeli Ministry of Health means that we can begin enrolling patients in a second country with a first class health care system," said Chris Stern, company chairman and CEO. "We hope this trial can provide data to show that Oxycyte is of invaluable importance in improving the outcome of patients, both civilian and military, with severe TBI. It is our goal to finally prove that there is a safe and effective treatment for this devastating injury."

The clinical trial with four centers in Israel is part of a larger study that also includes seven trial centers in Switzerland. The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI."

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluo
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
2. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
3. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
6. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
9. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
10. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... - Used during coronary angioplasty plus stenting, in patients ... reversible blood thinner did not have a significantly different ... mortality, heart attack and need for new procedures to ... significantly lessened the risk for two pre-specified single secondary ...
... , SILVER SPRING, Md., Nov. 13 ... Lysteda tablets (tranexamic acid), the first non-hormonal product cleared ... stabilizing a protein that helps blood to clot. ... Heavy menstrual bleeding is reported each year by about ...
Cached Medicine Technology:American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
(Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
(Date:4/24/2014)... for BrainHealth will bring together national experts to ... at its inaugural Brain Health Summit, titled "The ... will include Dr. Sandra Bond Chapman, founder and ... Senator Chuck Grassley (R-IA), U.S. Representative Chaka Fattah ... Policy and Early Learning, U.S. Department of Education. ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants ... a Lead Academic Participating Site in its new ... are a select groups of investigators charged with distributing ... groups., The NCTN grant system reflects recommendations from a ... operations to achieve four goals:, Faster design, ...
(Date:4/24/2014)... research led by a scientist at the University of ... element in the development of the nervous system may ... breast cancer., A research team, led by Dr ... Department of Biology at York, has studied how voltage-gated ... These channels are found in the membranes of excitable ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2
... India - Dr. Avul Pakir Jainulabdeen Abdul Kalam released ... Shri - on the eve of the Republic Day. ... Committee’ makes the final recommendations on awardees after receiving ... central ministries and departments and institutions of excellence, and ...
... network can target something like 100 billion nerve cells in ... other cells and organs in the body. How, then, do ... quick and precisely timed? ,A team at ... this mysterious mechanism. Their discovery could have important implications for ...
... shows LAG-3 protein on activated T lymphocytes slows replication until ... these cells to reproduce rapidly. ,The ... on specific targets is thrown into high gear when either ... the immune cells leading that battle, according to investigators at ...
... study finds that a simple blood test may be able ... neck cancer as a result of smoking. ... the Weizmann Institute's Biological Chemistry Department, Dr. Tamar Paz-Elizur of ... collaboration with of Tel Aviv-Sourasky Medical Center, Prof. Laurence ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... in the work place, China has kick-started a national// initiative- ... monitored by the International Labor Organization. The program is slated ... Xiaoyi, vice-minister of Labor and Social Security, during the launch ... stage in fighting HIV/AIDS. We should try our best to ...
Cached Medicine News:Health News:Majority of Padma Awards Go to Doctors from Delhi 2Health News:How Ion Channels are Organized to Control Nerve Cell Communication? 2Health News:Immune System Gears Up by Specific Enzymes 2Health News:Scientists Identity Genetic Risk Factor for Head and Neck Cancer 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2
... The Radionics OmniSight EXcel image guided ... while maintaining simplicity in design and ... allowing the surgeons to localize critical ... This new system gives surgeons an ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
... Convenient hand held quick and ... which is measured on the ... exophoria are measured by the ... be assessed by moving the ...
... Trial Clips have become a ... stand., ,These useful and inexpensive ... your patient's spectacle frame. Each ... lenses and the rubber coating ...
Medicine Products: